Shenzhen Lifotronic Technology Co., Ltd. (688389.SS)
CNY 15.22
(0.33%)
CNY 15.22
(0.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 375.48 Million CNY | 43.77% |
| 2022 | 287.1 Million CNY | 26.61% |
| 2021 | 224.78 Million CNY | 33.74% |
| 2020 | 169.24 Million CNY | 39.1% |
| 2019 | 123.42 Million CNY | 25.61% |
| 2018 | 98.45 Million CNY | 57.07% |
| 2017 | 61.36 Million CNY | 209.59% |
| 2016 | 21.58 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 57.06 Million CNY | -41.99% |
| 2024 Q3 | 80.89 Million CNY | 3.84% |
| 2024 Q1 | 136.92 Million CNY | 6.31% |
| 2023 Q3 | 75.54 Million CNY | 34.51% |
| 2023 Q1 | 101.47 Million CNY | -24.43% |
| 2023 FY | - CNY | 43.77% |
| 2023 Q4 | 155.06 Million CNY | 105.25% |
| 2023 Q2 | 56.16 Million CNY | -44.65% |
| 2022 Q3 | 19.1 Million CNY | -47.13% |
| 2022 Q2 | 36.13 Million CNY | -50.91% |
| 2022 Q1 | 73.61 Million CNY | -4.75% |
| 2022 FY | - CNY | 26.61% |
| 2022 Q4 | 134.27 Million CNY | 602.77% |
| 2021 Q3 | 41.63 Million CNY | 44.92% |
| 2021 FY | - CNY | 33.74% |
| 2021 Q4 | 77.27 Million CNY | 85.63% |
| 2021 Q2 | 28.72 Million CNY | -52.6% |
| 2021 Q1 | 60.6 Million CNY | -1.28% |
| 2020 Q4 | 61.39 Million CNY | 106.45% |
| 2020 Q3 | 29.73 Million CNY | -7.6% |
| 2020 Q1 | 35.61 Million CNY | -18.22% |
| 2020 FY | - CNY | 39.1% |
| 2020 Q2 | 32.18 Million CNY | -9.64% |
| 2019 Q2 | 21.47 Million CNY | -33.4% |
| 2019 FY | - CNY | 25.61% |
| 2019 Q4 | 43.54 Million CNY | 153.07% |
| 2019 Q3 | 17.2 Million CNY | -19.86% |
| 2019 Q1 | 32.24 Million CNY | -14.8% |
| 2018 Q4 | 37.84 Million CNY | 0.0% |
| 2018 FY | - CNY | 57.07% |
| 2017 FY | - CNY | 209.59% |
| 2016 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Chison Medical Technologies Co., Ltd. | 157.82 Million CNY | -137.912% |